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Open acAbstract Background and aims: Common non-coding variations within the TCF7L2 locus have
a strong influence on type 2 diabetes (T2D) susceptibility through uncharacterised mecha-
nisms. An islet-specific functional polymorphism has been identified, although this does not
explain the association between genotype and gene expression in other cell types. This study
sought to identify these other functional TCF7L2 variants.
Methods and results: Alternative splicing and gene expression from TCF7L2 was examined from
peripheral blood mononuclear cells from 100 healthy Caucasians using two T2D-associated
SNPs, rs7903146 and rs12255372. Electrophoretic mobility shift assays and luciferase reporter
assays were performed with these SNPs and those in strong LD to determine potential SNP
functionality.
Individuals homozygous for rs7903146 and rs12255372 T2D risk alleles (TT/TT) expressed 2.6-
fold greater levels of TCF7L2 mRNA compared to individuals homozygous for the non-risk
alleles (CC/GG, p Z 0.006), although differentially spliced TCF7L2 transcripts did not differ
by T2D risk-associated genotype. From SNPs identified to be in strong LD with the T2D-
associated SNPs, rs7903146 and rs12255372, five (rs4132670, rs4506565, rs7903146,
rs7901695, rs17747324) demonstrated allele-specific binding in electrophoretic mobility shift
assays (EMSA). In luciferase reporter assays, rs4132670 exhibited 1.3-fold higher levels of
enhancer activity in the Huh7 cell line (pZ 3.8  105) and 2-fold higher levels in a WiDr colon
carcinoma cell line (p Z 0.008).
Conclusions: These results suggest that rs4132670, located in a region of chromatin accessi-
bility, is a non-tissue-specific candidate functional SNP that has the potential to play a role
in TCF7L2 gene expression and T2D risk.
ª 2012 Elsevier B.V. Open access under CC BY license.mobility shift assay; FAIRE, Formaldehyde-assisted isolation of regulatory elements; GWAS, Genome-
tiplexed competitor-electrophoretic mobility shift assay; PBMC, Peripheral blood mononuclear cell;
nucleotide polymorphism; T2D, Type 2 diabetes mellitus.
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two T2D-associated SNPs were associated with alternativeThe risk of developing T2D is increased by environmental
factors such as obesity, sedentary lifestyle and nutrition
[1], however, there is a strong genetic component to
disease [2]. A genome-wide association study (GWAS) in
2006 identified a strong T2D susceptibility locus on chro-
mosome 10; the strongest association marked by the
microsatellite marker DG10S478 [3], and also by two
common SNPs: rs7903146 and rs12255372, located in
TCF7L2 intron 3 and 4, respectively. Individuals homozy-
gous for the risk-associated alleles were more than twice as
likely to develop T2D as non-carriers. Subsequent studies
have replicated this association in prospective and case-
econtrol cohorts in a range of populations [4e6].
TCF7L2 is a member of the high mobility group box
family of transcription factors, activated by the WNT-
signalling pathway. Illustrated in Fig. 1, the gene spans
215.9 kb and comprises 17 exons. The gene possesses two
major domains: a catenin-binding domain (exon 1) and
a central DNA-binding HMG domain (exons 10 and 11) [7]. At
least five exons can be alternatively spliced [8] and most
human tissues express detectable levels of this transcrip-
tion factor [9]. Although the T2D-associated SNPs are
located in non-coding regions it is not clear if these SNPs, or
a variant in strong linkage disequilibrium (LD) with these,
play a role in alternative splicing, gene expression, or
protein structure.
The mechanisms leading to T2D from TCF7L2 remain
unknown, as indeed, to which cell types this ubiquitously
expressed gene may be playing a role in disease patho-
genesis. One obvious potential target tissue is the pancre-
atic islets, and a study of TCF7L2 in this tissue
demonstrated increased gene expression in risk allele
carriers [10]. Another study investigated TCF7L2 gene
expression and splicing in additional potential target
tissues: adipose and muscle tissue [11]. In contrast to the
study in pancreatic islets, certain splice forms in subcuta-
neous adipose tissue were associated with reduced TCF7L2
gene expression in individuals homozygous for the
rs7903146 T risk alleles, but overall TCF7L2 gene expression
was not significantly associated with rs7903146 genotype.
It was relatively recently proposed that obesity, insulin
resistance and T2D are chronic inflammatory diseases, and
much research is currently involved with understanding the
role of the body’s immune cells in metabolic imbalanceFigure 1 Structure of the TCF7L2 gene. Arrows indicate transcri
alternatively spliced exons. Round lines between exons indicate al[12]. The aim of this study was to determine whether the
splicing or differences in gene expression levels, using
peripheral blood mononuclear cells (PBMCs) as the poten-
tial target of TCF7L2 expression in T2D pathogenesis. A
previously reported pancreatic islet-specific functional
polymorphism has been reported [13], however, this SNP is
also associated with increased gene expression in a number
of tissues, suggesting that either this SNP or another in
strong LD has additional unreported functionality. We
looked for further functional SNPs in LD with the TCF7L2
SNPs associated with T2D from GWAS, that were not
pancreatic-specific, since these may also have an as-yet
unknown role in T2D pathogenesis. Locating all the causal
variants will lead to a better capacity to predict disease,
determine the mechanism of genetic susceptibility and
guide the development of novel therapeutics.
Methods
See supplement for a description of the methods used.
Results
Genotyping of rs7903146 and rs12255372
To investigate the association between TCF7L2 genotype
and mRNA splicing patterns a cohort of 100 healthy indi-
viduals were genotyped for the two SNPs associated with
T2D risk (rs7903146 and rs12255372). The genotype distri-
bution was in HardyeWeinberg equilibrium and the
frequencies consistent with previous studies [4e6]
(rs7903146 (IVS3 Cgt; T): 55% CC, 37% CT, 8% TT, minor
allele frequency (MAF) Z 0.34, rs12255372 (IVS4 Ggt; T):
56% GG, 31% GT, 13% TT. MAF Z 0.36).
TCF7L2 exon 4 splicing
To examine splicing of TCF7L2 exon 4 in individuals with
TCF7L2 T2D risk genotypes, a probe overlapping the exon
3/4 border and another overlapping the exon 3/5 border
was used. The exon 3/4 probe identified PCR product from
mRNA transcripts including exon 4, while the exon 3/5
probe identified mRNA transcripts that did not. No statis-
tically significant difference between the relativeption start sites. Grey bars indicate exons. Black bars indicate
ternative splicing products.
Figure 2 A, B and C. Relative expression (þS.E.M.) of TCF7L2
mRNA transcripts by genotype, compared to the non-risk
alleles CC (rs7903146) and GG (rs12255372). A) Comparison of
TCF7L2 transcripts with exon 4 present or exon 4 absent (p-
value for trend using additive model: exon 4 in, pZ 0.03; exon
4 out, p Z 0.02) B) Comparison of TCF7L2 transcripts with the
exon 9 splice acceptor site present (exon 9 L) or absent (exon
9 S) (p-value for trend using additive model: exon 9S pZ 0.01;
exon 9 l, p Z 0.04). C) Comparison of TCF7L2 transcripts with
exons 1 and 2 (exon 1/2 P) or without exons 1 and 2 (exon 1/2
A) (p-value for trend using additive model; exon 1/2A,
p Z 0.01; exon 1/2P, p Z 0.008).
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observed when stratified by T2D risk genotypes (rs7903146
and rs12255372, Fig. 2A); indicating that alternative
splicing of exon 4 was not affected by these T2D risk alleles.
However, individuals homozygous for the rare alleles of
both rs7903146 and rs12255372 expressed significantly more
TCF7L2 transcript than individuals homozygous for the
common alleles (2.6-fold for transcripts with exon 4
p Z 0 < 0.01 and 2.89-fold for transcripts lacking exon 4,
p < 0.01).
TCF7L2 exon 9 splicing
Exon 9 has an alternative splice acceptor site which adds 15
base pairs to its 50 end. TaqMan probes were customized to
span the exon 8/9 boundary, including or excluding the 15
base pairs. No statistically significant difference between
rs7903146 and rs12255372 genotype and relative amounts
of exon 9 short and exon 9 long was observed (Fig. 2B).
Individuals homozygous for the rare allele expressed
significantly more TCF7L2 transcript than individuals
homozygous for the common allele (2.4-fold for transcripts
with the splice acceptor site p Z 0.03 and 2.6-fold for
transcripts lacking the additional 15 base pairs pZ 0.032).
Exon 1/2 splicing
To examine whether the putative splicing of exons 1 and 2
was associated with T2D risk alleles, two Taqman probes
that spanned either the exon 1/2 boundary or the exon 5/6
boundary were used. The exon 1/2 probe spans exons 1 and
2 and the exon 5/6 probe was used to identify total mRNA
transcript regardless of splicing, as exons 5 and 6 are not
spliced. As shown in Fig. 2C, splicing of exons 1 and 2 does
occur. However, as with exon 4 and 9, no statistically
significant difference between rs7903146 and rs12255372
genotype and relative amounts of transcripts containing
exons 1/2 and those without was observed. As with exon 4
and exon 9, homozygotes carrying the rare alleles express
significantly more TCF7L2 transcript than individuals
homozygous for the common allele (2.25-fold increase in
transcripts containing exons 1 and 2, 2.3-fold increase for
transcripts without exons 1 and 2, p < 0.05 for both).
Electrophoretic mobility shift assay
Gene expression data suggested that TCF7L2 T2D risk
alleles act through gene expression levels rather than
alternative splicing. To investigate whether differences in
TCF7L2 mRNA levels observed were due to differential
transcription factor binding to TCF7L2 risk alleles, elec-
trophoretic mobility shift assays (EMSA) were performed.
Linkage disequilibrium (LD) data from Caucasian pop-
ulations (HapMap 3, release 2, http://gvs.gs.washington.
edu/GVS/index.jsp and the 1000 Genomes Project [20])
were used to identify five additional SNPs in strong LD with
the original GWAS SNPs associated with T2D (Fig. 3). EMSA
was performed using probes that contained both alleles of
all seven SNPs using nuclear extract the WiDr colon carci-
noma cell line, a cell line that expresses high levels of
TCF7L2. An allele-specific binding pattern was identified in
Figure 3 Linkage disequilibrium between SNPs in high LD with rs7903146 and rs12255372 and their relative positions in TCF7L2
(Haploview).
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rs7901695, rs17747324 (Fig. 4).
Luciferase assay
Luciferase reporter assays examined whether variants that
altered in vitro binding, also had allelic enhancer effects,
influencing TCF7L2 transcription. The original T2D-
associated SNPs rs7903146 and rs12255372 were also
included in this analysis. Allele-specific luciferase reporter
constructs were designed with genomic sequences
surrounding TCF7L2 SNPs inserted downstream of the
luciferase gene, driven by the TCF7L2 minimal promoter.
Luciferase activity was measured in the Huh7 and WiDr cell
lines, two cell lines that express TCF7L2.
When both cell lines were transfected with the T allele
of the rs4132670 reporter constructs, significantly higher
luciferase activity was observed compared to cells trans-
fected with the C-allele (Huh7, 1.3-fold, p Z 3.8  105;
WiDr, 2-fold, p Z 0.008) (Fig. 5A and Fig. 5B).Figure 4 EMSA analysis to determine allele-specific binding
differences. SNPs in strong LD with/including TCF7L2 T2D risk
SNPs. Allele-specific binding differences are highlighted. 1:
rs4132670, 2: rs4506565, 3: rs12243326, 4: rs7903146, 5:
rs12255372, 6: rs7901695, 7: rs17747324. Alleles are indicated
above image.Of the remaining SNPs, there were no consistent allelic
effects on expression in both cell types. For two SNPs,
however, there were tissue-specific effects on enhancer
activity. Huh7 cell lines transfected with the C-allele of
rs4506565 displayed 1.3-fold lower luciferase activity when
compared to cells containing the T allele (p Z 5.6  105
Fig. S1a). Huh7 cell lines transfected with the T allele of
rs12255372 displayed a 1.15-fold higher luciferase activity
compared to cells transcfected with the G-allele (pZ 0.02,
Fig. S1b). There was no difference in luciferase activity for
cells transfected with either of the rs7903146 alleles.In silico SNP analysis
For a functional SNP to act as an enhancer it is likely to
occur in an accessible region of chromatin, such as that
identified by DNase I hypersensitivity or formaldehyde-
assisted identification of regulatory elements (FAIRE).
Examination of annotated global maps of DNase I hyper-
sensitivity in 22 cell lines [23] revealed that of the SNPs
examined that altered DNA-binding, only rs4132670 was
located within a DNase I hypersensitive region. The T allele
of rs4132670 is in strong LD with the T allele of rs7903146.
Resequencing this DNase I hypersensitive region in 7 healthy
Caucasians of known genotype (3 CC, 2 CT, 2 TT individuals)
did not identify any further variation that was in strong LD
with the T2D risk SNP (data not shown).Multiplexed competitor EMSA
To determine the DNA-binding factor responsible for
binding to the rs4132670 T allele, multiplexed competitor
EMSA (MC-EMSA [14]) was carried out. This procedure
screens for binding using cocktails of DNA competitors for
a number of well-characterised DNA-binding proteins and
included those predicted to bind through in silico software
(MatInspector). MC-EMSA showed that rs4132670 T binding
Figure 5 TCF7L2 promoter expression (þS.E.M.) as a func-
tion of rs4132670 genotype. Expression levels are normalized
to pGL3 basic vector with only the TCF7L2 minimal promoter
(control). A) Huh7 cells were transfected with pGL3 basic
vectors containing the TCF7L2 promoter with a fragment of
rs4132670 subcloned into the enhancer site of pGL3. B) WiDr
cells were transfected with pGL3 basic vectors containing the
TCF7L2 promoter with a fragment of rs4132670 subcloned into
the enhancer site of pGL3.
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(Supplementary Fig. 4B and C).Discussion
A number of studies have replicated the findings by Grant
et al. [3] demonstrating association between two intronic
SNPs in TCF7L2 and T2D [4e6]. The functionality of these
SNPs and those in strong LD were explored using these
markers with the aim of identifying further putative causal
variants and the mechanism by which these may exert their
effects.
Although TCF7L2 transcription results in a number of
alternatively spliced mRNA products, the causal effect of
the T2D genetic risk variants are unlikely to be mediated by
alternative splicing. There are no SNPs in high LD with T2D-associated SNPs located in splice-donor/acceptor sites, and
there was no significant difference in splicing of exons 1/2,
4 or nucleotides 1e15 of exon 9 in PBMC mRNA between
subjects of different genotype. The putative splice sites at
exons 13e17 are in a region of very low LD from the T2D risk
alleles, and are unlikely to be influenced by these SNPs [8].
This result is in line with previous studies which have found
very little evidence for TCF7L2 splicing to be associated
with risk of T2D [15e17]. However, there was a significant
association between the risk variants and increased TCF7L2
gene expression levels. Individuals homozygous for the rare
allele T at both SNP positions produce w2.5-fold the levels
of TCF7L2 transcript compared to wild-type individuals
while individuals heterozygous for both alleles produced
w1.5-fold more transcript. Our data derives from PBMCs,
although it is consistent with findings from a similar study
on pancreatic TCF7L2 gene expression in risk allele carriers
[10].
Interestingly, TCF7L2 transcripts that do not contain
exons 1 and 2 are produced in equal quantity as transcripts
that do contain exon 1, regardless of genotype. Exon 1
codes for the b-catenin binding domain, and half the mRNA
transcripts produced may therefore code for an isoform of
TCF7L2 that does not respond to b-catenin. It is unknown
whether this variant is able to bind to TCF7L2 target genes,
and if so, whether it is able to participate in gene
regulation.
A study by Mondal et al. [11] investigated TCF7L2 gene
expression and splicing in adipose and muscle tissue. The
authors found that certain splice forms in subcutaneous
adipose tissue are associated with reduced TCF7L2 gene
expression in individuals homozygous for the rs7903146 T
risk alleles, but that overall TCF7L2 gene expression was
not significantly associated with rs7903146 genotype. This
finding in adipose tissue is in contrast to our finding in
blood, and may reflect tissue-specific differences in
enhancer usage between adipose and blood tissues, and
a SNP in strong LD with the rs7903146 that may affect
alternative splicing only in adipose tissue. However,
a previous study by Lyssenko et al. which measured TCF7L2
mRNA in pancreatic islets from 7 T2D and 15 nondiabetic
human cadaveric organ donors [10] found higher gene
expression was associated with rs7903146 and rs12255372 T
alleles. Individuals homozygous for the rare T alleles
expressed 3.3-fold (pZ 0.02) as much TCF7L2 transcript as
individuals possessing the common CC/GG genotype. The
concordant results from this study in PBMCs and the study in
pancreatic b-cells suggests that there may be a common
mechanism by which the T2D risk alleles are influencing
gene expression in these tissues.
Despite the relationship between the TCF7L2 T2D risk
alleles and increased gene expression, there is little
evidence identifying causal allele/s. Gaulton et al exam-
ined the presence of putative regulatory elements specific
to pancreatic islet cells [13]. Using FAIRE-seq, the authors
identified w80,000 open chromatin sites of which w3300
were islet-selective. The TCF7L2 SNP rs7903146 was located
within an islet-selective open chromatin region. The T
allele was found to show significantly greater enhancer
activity than the C allele in two islet b-cell lines using
reporter assays. However, this finding contradicts the
allele-specific TCF7L2 mRNA expression common to both
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strong LD with rs7903146 or rs12255372 and performed
EMSA and reporter assays on these. Cell lines used for these
experiments were the colon and a liver cell line, which both
expresses high levels of TCF7L2 (data not shown), and were
used to provide conformation of non-tissue-specific tran-
scriptional effects. Of the three SNPs that influenced
TCF7L2 enhancer activity in the luciferase reporter assays,
the rare C-allele of rs4506565 significantly decreased TC7L2
transcription, contrary to the well-established observation
that rs7903146 TT individuals produce more TCF7L2 tran-
script. The rare T allele of rs12255372 was found to
moderately (1.15-fold, p Z 0.02) increase reporter
expression levels in Huh7 cell only. In both cases, reporter
assays in WiDr cell remained non-significant, indicating
a possible liver tissue-specific response. The T allele of
rs4132670 was associated with increased reporter expres-
sion levels in both WiDr and Huh7 cell lines.
EMSA analysis indicated that binding to rs4132670 T may
be due to binding similarity to the cis-inducible element
(SIE). SIE is known to bind STAT1-STAT1 and STAT1-STAT3
dimers [18]. The JAK-STAT pathway can be activated by
IFN-g and IL-6, along with several other cytokines, and
there may be an interaction between these biomarkers and
rs4132670: individuals that possess the rs4132670 T allele
may have higher levels of STAT1-STAT3 binding to the
TCF7L2 enhancer, leading to increased expression levels,
which will be exacerbated under chronic inflammatory
stimuli, potentially leading to higher T2D in these
individuals.
Although we looked at a relatively large number of
PBMCs in our analysis of gene expression, we did not
examine other tissues that may play a role in disease.
However, the results from our in vivo expression assays
using PBMCs were correlated with the expression levels of
reporter gene in both liver and colon cells, indicating that
this effect is unlikely to be tissue-specific. In addition to
the functional analysis shown here, rs4132670 was located
within a regulatory region identified by global mapping of
DNase I hypersensitivity and FAIRE sites in a number of cell
lines including aortic smooth muscle cells, liver, fibroblasts,
lymphoblastoid cells, bronchial epithelial cells and
epidermal keratinocytes [19] (supplementary Fig. 6). This
gives additional lines of evidence to suggest that this area
harbours an important regulatory region.
This candidate functional SNP is in strong LD with the
two T2D risk SNPs identified by GWAS, with an r2 of 0.93 and
0.98 for rs7903146 and rs12255372, respectively, in Cauca-
sians. The strong LD between rs4132670 and the T2D GWAS
SNPs in Caucasians would mean that substitution by
rs4132670 will, at best, result in only a modest improve-
ment to T2D risk assessment, and to show such an effect
would require a very large caseecontrol study. Whether the
two candidate functional SNPs rs7903146 and rs4132670
may act in concert or in an additive manner to affect
disease risk remains to be determined.Acknowledgements
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